Deadline for Registration Approaching: Bronstein, Gewirtz & Grossman LLC Provides Final Reminder.

A class action lawsuit has been initiated against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and specific individuals associated with the company. The lawsuit alleges violations of federal securities laws and seeks to recover damages on behalf of shareholders who acquired Regeneron stock between October 19, 2020, and August 10, 2021.

The legal complaint asserts that during the specified period, Regeneron made false and misleading statements regarding the efficacy of the company’s monoclonal antibody COVID-19 treatment, REGEN-COV. These claims were allegedly made to boost Regeneron’s stock price artificially. The lawsuit suggests that Regeneron’s statements led investors to believe that REGEN-COV was a highly effective treatment for COVID-19, resulting in an inflated stock value.

The lawsuit claims that Regeneron’s alleged misleading statements caused significant financial losses for investors who purchased Regeneron stock during the specified time frame. Investors who suffered losses as a result of relying on misleading information are eligible to participate in the class action lawsuit.

Regeneron Pharmaceuticals is accused of violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. These provisions prohibit the use of deceptive practices in connection with the purchase or sale of securities. The lawsuit against Regeneron seeks to hold the company accountable for its alleged misconduct and recover damages for affected shareholders.

Investors who wish to join the class action lawsuit against Regeneron must act promptly to ensure their eligibility. The lawsuit is currently in progress, and investors who acquired Regeneron stock during the specified period may be entitled to compensation for their losses. By participating in the legal action, shareholders have the opportunity to seek justice for the alleged securities law violations committed by Regeneron Pharmaceuticals.

It is essential for investors to understand their rights and options regarding the class action lawsuit against Regeneron. By staying informed about the proceedings and seeking legal counsel if necessary, investors can protect their interests and potentially recover losses resulting from alleged securities fraud. The lawsuit represents an effort to hold Regeneron accountable for its actions and provide restitution for affected shareholders.